NCT06297980 Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
| NCT ID | NCT06297980 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Type 1 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-24 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2024-03-24 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objectives of this study are to examine how sex hormones (use of hormonal birth control, menstrual cycle phase) impact glycemic control among women with type 1 diabetes (T1D), and to test adjustments to insulin dosing and food intake to ameliorate cycle-related glycemic variability. A secondary aim is to examine how the menstrual cycle and use of hormonal birth control impact patient-reported outcomes and glycemic responses to physical activity.
Eligibility Criteria
Inclusion Criteria: * Women 18-45 who have had type 1 diabetes for at least 12 months * Premenopausal with either menstrual cycles or currently using oral contraceptives Exclusion Criteria: * Women who are postmenopausal, pregnant, trying to become pregnant, or have had a hysterectomy
Contact & Investigator
JANET K SNELL-BERGEON, PhD, MPH
PRINCIPAL INVESTIGATOR
University of Colorado, Denver
Frequently Asked Questions
Who can join the NCT06297980 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Type 1 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06297980 currently recruiting?
Yes, NCT06297980 is actively recruiting participants. Contact the research team at Janet.Snell-Bergeon@cuanschutz.edu for enrollment information.
Where is the NCT06297980 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT06297980 clinical trial?
NCT06297980 is sponsored by University of Colorado, Denver. The principal investigator is JANET K SNELL-BERGEON, PhD, MPH at University of Colorado, Denver. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.